- Home
- FURY vs ONCY Comparison
FURY vs ONCY Comparison
Compare FURY & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- ONCY
- Stock Information
- Founded
- FURY 2008
- ONCY 1998
- Country
- FURY Canada
- ONCY Canada
- Employees
- FURY N/A
- ONCY N/A
- Industry
- FURY Precious Metals
- ONCY Pharmaceuticals and Biotechnology
- Sector
- FURY Basic Materials
- ONCY Health Care
- Exchange
- FURY Nasdaq
- ONCY Nasdaq
- Market Cap
- FURY 60.5M
- ONCY 53.6M
- IPO Year
- FURY N/A
- ONCY 1999
- Fundamental
- Price
- FURY $0.40
- ONCY $0.56
- Analyst Decision
- FURY Strong Buy
- ONCY Strong Buy
- Analyst Count
- FURY 1
- ONCY 4
- Target Price
- FURY $1.10
- ONCY $4.00
- AVG Volume (30 Days)
- FURY 133.2K
- ONCY 224.8K
- Earning Date
- FURY 05-13-2025
- ONCY 03-07-2025
- Dividend Yield
- FURY N/A
- ONCY N/A
- EPS Growth
- FURY N/A
- ONCY N/A
- EPS
- FURY N/A
- ONCY N/A
- Revenue
- FURY N/A
- ONCY N/A
- Revenue This Year
- FURY N/A
- ONCY N/A
- Revenue Next Year
- FURY N/A
- ONCY N/A
- P/E Ratio
- FURY N/A
- ONCY N/A
- Revenue Growth
- FURY N/A
- ONCY N/A
- 52 Week Low
- FURY $0.35
- ONCY $0.55
- 52 Week High
- FURY $0.59
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- FURY 49.92
- ONCY 27.91
- Support Level
- FURY $0.39
- ONCY $0.58
- Resistance Level
- FURY $0.42
- ONCY $0.65
- Average True Range (ATR)
- FURY 0.02
- ONCY 0.03
- MACD
- FURY -0.00
- ONCY -0.00
- Stochastic Oscillator
- FURY 25.00
- ONCY 1.34
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.